Equities

Avanos Medical Inc

Avanos Medical Inc

Actions
  • Price (EUR)18.30
  • Today's Change-0.40 / -2.14%
  • Shares traded400.00
  • 1 Year change-7.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments88128119
Total Receivables, Net143168131
Total Inventory163190159
Prepaid expenses291419
Other current assets, total65----
Total current assets487500428
Property, plant & equipment, net144195207
Goodwill, net796819802
Intangibles, net240251141
Long term investments------
Note receivable - long term------
Other long term assets191817
Total assets1,6921,7871,604
LIABILITIES
Accounts payable566856
Accrued expenses10611283
Notes payable/short-term debt000
Current portion long-term debt/capital leases8.606.200
Other current liabilities, total64----
Total current liabilities235186139
Total long term debt159226130
Total debt168233130
Deferred income tax242512
Minority interest------
Other liabilities, total385852
Total liabilities456496333
SHAREHOLDERS EQUITY
Common stock0.500.500.50
Additional paid-in capital1,6641,6461,629
Retained earnings (accumulated deficit)(315)(253)(304)
Treasury stock - common(86)(67)(21)
Unrealized gain (loss)(27)(36)(34)
Other equity, total00.30--
Total equity1,2361,2911,271
Total liabilities & shareholders' equity1,6921,7871,604
Total common shares outstanding464748
Treasury shares - common primary issue3.040.320.32
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.